Gregory R. Steinberg

Gregory R. Steinberg

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Gregory R. Steinberg

Centre for Metabolism, Obesity and Diabetes Research, McMaster University, Hamilton, ON L8N 3Z5, Canada; Division of Endocrinology and Metabolism, Department of Medicine, McMaster University, Hamilton, ON L8N 3Z5, Canada

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2009 in Physiological Reviews
Verified
Journal Article
Closed access
PDF file
GSGregory R. Steinberg
Gregory R. Steinberg
BKBruce E. Kemp
Bruce E. Kemp
The function and survival of all organisms is dependent on the dynamic control of energy metabolism, when energy demand is matched to energy supply. The AMP-activated protein kinase (AMPK) αβγ heterotrimer has emerged as an important integrator of signals that control energy balance through the regulation of multiple biochemical pathways in all eukaryotes. In this review, we begin with the discovery of the AMPK family and discuss the recent structural studies that have revealed the molecular basis for AMP binding to the enzyme's γ subunit. AMPK's regulation involves autoinhibitory features and phosphorylation of both the catalytic α subunit and the β-targeting subunit. We review the role of AMPK at the cellular level through examination of its many substrates and discuss how it controls cellular energy balance. We look at how AMPK integrates stress responses such as exercise as well as nutrient and hormonal signals to control food intake, energy expenditure, and substrate utilization at the whole body level. Lastly, we review the possible role of AMPK in multiple common diseases and the role of the new age of drugs targeting AMPK signaling.

1 March 2010 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
SGSandra Galic
Sandra Galic
Jonathan S. OakhillJonathan S. Oakhill
Jonathan S. Oakhill
GSGregory R. Steinberg
Gregory R. Steinberg

6 February 2020 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
HLHyemin Lee
Hyemin Lee
FZFereshteh Zandkarimi
Fereshteh Zandkarimi
YZYilei Zhang
Yilei Zhang
JMJitendra Kumar Meena
Jitendra Kumar Meena
JKJongchan Kim
Jongchan Kim
BGBoyi Gan
Boyi Gan

31 October 2022 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Closed access
PDF file
GSGregory R. Steinberg
Gregory R. Steinberg
DHDavid Grahame Hardie
David Grahame Hardie

3 November 2013 in Nature Medicine
Verified
Journal Article
Open access
PDF file
MFMorgan D Fullerton
Morgan D Fullerton
SGSandra Galic
Sandra Galic
KMKatarina Marcinko
Katarina Marcinko
SSSarah Sikkema
Sarah Sikkema
Dr. Thomas PulinilkunnilDr. Thomas Pulinilkunnil
Dr. Thomas Pulinilkunnil
GSGregory R Steinberg
Gregory R Steinberg
Metformin is one of the most widely prescribed therapeutics for type 2 diabetes. But exactly how it works is still unclear. Gregory Steinberg and colleagues now show that it does so by activation of the enzyme AMP-activated protein kinase (Ampk) and Ampk's obligate targeting of two key enzymes involved in lipid homeostasis. The obesity epidemic has led to an increased incidence of nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. AMP-activated protein kinase (Ampk) regulates energy homeostasis and is activated by cellular stress, hormones and the widely prescribed type 2 diabetes drug metformin1,2. Ampk phosphorylates mouse acetyl-CoA carboxylase 1 (Acc1; refs. 3,4) at Ser79 and Acc2 at Ser212, inhibiting the conversion of acetyl-CoA to malonyl-CoA. The latter metabolite is a precursor in fatty acid synthesis5 and an allosteric inhibitor of fatty acid transport into mitochondria for oxidation6. To test the physiological impact of these phosphorylation events, we generated mice with alanine knock-in mutations in both Acc1 (at Ser79) and Acc2 (at Ser212) (Acc double knock-in, AccDKI). Compared to wild-type mice, these mice have elevated lipogenesis and lower fatty acid oxidation, which contribute to the progression of insulin resistance, glucose intolerance and NAFLD, but not obesity. Notably, AccDKI mice made obese by high-fat feeding are refractory to the lipid-lowering and insulin-sensitizing effects of metformin. These findings establish that inhibitory phosphorylation of Acc by Ampk is essential for the control of lipid metabolism and, in the setting of obesity, for metformin-induced improvements in insulin action.

1 October 2006 in Diabetes
Verified
Journal Article
Closed access
PDF file
ACAndrew Carey
Andrew Carey
GSGregory R. Steinberg
Gregory R. Steinberg
SMS. Lance Macaulay
S. Lance Macaulay
WTWalter G. Thomas
Walter G. Thomas
AHAnna G. Holmes
Anna G. Holmes
MFMark A. Febbraio
Mark A. Febbraio
Although interleukin-6 (IL-6) has been associated with insulin resistance, little is known regarding the effects of IL-6 on insulin sensitivity in humans in vivo. Here, we show that IL-6 infusion increases glucose disposal without affecting the complete suppression of endogenous glucose production during a hyperinsulinemic-euglycemic clamp in healthy humans. Because skeletal muscle accounts for most of the insulin-stimulated glucose disposal in vivo, we examined the mechanism(s) by which IL-6 may affect muscle metabolism using L6 myotubes. IL-6 treatment increased fatty acid oxidation, basal and insulin-stimulated glucose uptake, and translocation of GLUT4 to the plasma membrane. Furthermore, IL-6 rapidly and markedly increased AMP-activated protein kinase (AMPK). To determine whether the activation of AMPK mediated cellular metabolic events, we conducted experiments using L6 myotubes infected with dominant-negative AMPK α-subunit. The effects described above were abrogated in AMPK dominant-negative–infected cells. Our results demonstrate that acute IL-6 treatment enhances insulin-stimulated glucose disposal in humans in vivo, while the effects of IL-6 on glucose and fatty acid metabolism in vitro appear to be mediated by AMPK.